Mesoblast Quote - MESO

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

17.23

Bid

16.67

Offer

17.23

Volume

1,149,096

15.40 Day's Range 17.49

0.00 52 Week Range 0.00

Market Cap

1.967B

Previous Close

14.63

Open

15.72

Last Trade

Last Trade Time

08:46:36

Financial Volume

US$ 18,647,478

VWAP

16.228

Average Volume (3m)

Shares Outstanding

114,178,411

Dividend Yield

PE Ratio

-3.27

Earnings Per Share (EPS)

-0.77

Revenue

9.25M

Net Profit

-87.96M

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-... Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.mesoblast.com

Headquarters

Melbourne, Victoria, Aus

Founded

Mesoblast Limited is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker MESO. The last closing price for Mesoblast was US$14.63. Over the last year, Mesoblast shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Mesoblast currently has 114,178,411 shares in issue. The market capitalisation of Mesoblast is US$1.67 billion. Mesoblast has a price to earnings ratio (PE ratio) of -3.27.

Overall Flow

Bullish

Net Premium

560k

Calls / Puts

375.00%

Buys / Sells

63.64%

OTM / ITM

18.75%

Sweeps Ratio

0.00%

Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and...

Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming...

Form F-3 - Registration statement by foreign private issuers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

MESO - Frequently Asked Questions (FAQ)

What is the current Mesoblast share price?

The current share price of Mesoblast is US$ 17.23

How many Mesoblast shares are in issue?

Mesoblast has 114,178,411 shares in issue

What is the market cap of Mesoblast?

The market capitalisation of Mesoblast is USD 1.67B

What is the 1 year trading range for Mesoblast share price?

Mesoblast has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Mesoblast?

The price to earnings ratio of Mesoblast is -3.27

What is the cash to sales ratio of Mesoblast?

The cash to sales ratio of Mesoblast is 31.11

What is the reporting currency for Mesoblast?

Mesoblast reports financial results in USD

What is the latest annual turnover for Mesoblast?

The latest annual turnover of Mesoblast is USD 9.25M

What is the latest annual profit for Mesoblast?

The latest annual profit of Mesoblast is USD -87.96M

What is the registered address of Mesoblast?

The registered address for Mesoblast is LEVEL 38, 55 COLLINS STREET, MELBOURNE, VICTORIA, 3000

What is the Mesoblast website address?

The website address for Mesoblast is www.mesoblast.com

Which industry sector does Mesoblast operate in?

Mesoblast operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NCRANocera Inc	US$ 1.68 (88.66%)	3.18M
MYNAMynaric AG	US$ 0.6998 (59.18%)	4.31M
BNOXBionomics Ltd	US$ 0.352 (39.08%)	5.36M
MKDWMKDWELL Tech Inc	US$ 1.13 (13.00%)	35.34k
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.4504 (11.73%)	10.18M
SLGLSol Gel Technologies Ltd	US$ 1.04 (-36.97%)	2.26M
DRCTDirect Digital Holdings Inc	US$ 3.98 (-27.64%)	4.82M
CHEKCheck Cap Ltd	US$ 1.70 (-24.44%)	816.67k
AVGRAvinger Inc	US$ 0.5666 (-11.80%)	87.9k
VIVKVivakor Inc	US$ 1.16 (-11.45%)	240
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.4504 (11.73%)	10.18M
BNOXBionomics Ltd	US$ 0.352 (39.08%)	5.36M
DRCTDirect Digital Holdings Inc	US$ 3.98 (-27.64%)	4.82M
MYNAMynaric AG	US$ 0.6998 (59.18%)	4.31M
SOFISoFi Technologies Inc	US$ 15.6299 (-0.00%)	4.16M